Multiple myeloma trials in United States

In United States 297 Also abroad 703

297 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Where
Houston
People
34
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT07382739
Phase 1/2Taking people
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Where
Atlanta, Houston, Louisville, New York, Omaha
Age
18 years and over
People
78 worldwide
Run by
Heidelberg Pharma AG
See details and how to joinNCT04879043 · EU 2024-515273-10-00
Phase 1Taking people
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Where
San Francisco
Age
18 years and over
People
20
Run by
Robert Flavell, MD, PhD
See details and how to joinNCT05892393
Phase 2Taking people
ELISA in Relapsed/Refractory MM
Where
Boston
Age
18 years and over
People
30
Run by
Massachusetts General Hospital
See details and how to joinNCT06832865
Phase 1/2Taking people
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Where
Seattle
Age
18 years and over
People
30
Run by
Fred Hutchinson Cancer Center
See details and how to joinNCT07181941
No phaseTaking people
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
Where
Sacramento
Age
21 years and over
People
4,000
Run by
University of California, Davis
See details and how to joinNCT04314752
Phase 2Taking people
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Where
New York
Age
70 years and over
People
23
Run by
Larysa Sanchez
See details and how to joinNCT06827860
Phase 2Taking people
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Where
Anchorage
Age
18 years and over
People
74
Run by
Eastern Cooperative Oncology Group
See details and how to joinNCT07085728
Phase 2Taking people
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Where
Columbia, Denver, Eugene, Las Vegas, Nashville
Age
18 years and over
People
46
Run by
SCRI Development Innovations, LLC
See details and how to joinNCT07637578
Phase 2Taking people
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Where
Atlanta
Age
18 years and over
People
34
Run by
Emory University
See details and how to joinNCT05208307
Phase 2Taking people
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Where
Durham
Age
18 years and over
People
27
Run by
Duke University
See details and how to joinNCT06822972
Phase 1/2Not yet taking people in United States
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
Where
Boston
Age
18 years and over
People
88
Run by
Dana-Farber Cancer Institute
See details and how to joinNCT07601100
Phase 1/2Taking people
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Birmingham, Hackensack, Houston, New Haven
Age
18 years and over
People
62 worldwide
Run by
Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00
Phase 2Not yet taking people in United States
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
Where
Little Rock
Age
18 years to 75 years
People
50
Run by
University of Arkansas
See details and how to joinNCT07029776
Phase 2Taking people
Elranatamab in R/R Multiple Myeloma
Where
Boston
Age
18 years and over
People
32
Run by
Massachusetts General Hospital
See details and how to joinNCT06138275
Phase 1/2Taking people
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Where
Madison
Age
18 years and over
People
62
Run by
Natalie Callander
See details and how to joinNCT07479979
Phase 2Taking people
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Where
Chicago, Salt Lake City
Age
18 years and over
People
50
Run by
University of Illinois Chicago
See details and how to joinNCT05344833
Phase 1Taking people
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Where
Boston, Hillsborough, Jacksonville, Nashville, New York, Orange, Phoenix, Rochester
Age
18 years and over
People
130 worldwide
Run by
Jiangsu Simcere Pharmaceutical Co., Ltd.
See details and how to joinNCT06375044
Phase 1Taking people
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Where
Atlanta, Boston, Duarte, Hackensack, Palo Alto, Portland, San Francisco, Tampa
Age
18 years and over
People
70 worldwide
Run by
Kelonia Therapeutics, Inc.
See details and how to joinNCT07075185
Phase 2Taking people
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Where
Rochester
Age
18 years and over
People
44
Run by
Mayo Clinic
See details and how to joinNCT06940297
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Where
Baton Rouge, Bethesda, Bridgeton, Farmington, Fort Myers, Los Alamitos, Macon, Nashville, Norwich, Springfield, Torrance, Whittier
Age
18 years and over
People
200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00
No phaseNot yet taking people in United States
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
Where
Burlington
Age
18 years and over
People
33
Run by
University of Vermont Medical Center
See details and how to joinNCT07783607
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Aventura, Basking Ridge, Clovis, Commack, Coral Gables, Coral Springs, Deerfield Beach, Fort Collins, Fresno, Greeley, Harrison, Hollywood, Loveland, Metairie, Miami, Middletown, Montvale, New York, Plantation, Uniondale
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 1/2Taking people
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Where
Canton, Wilson
Age
18 years and over
People
24
Run by
Starton Therapeutics, Inc
See details and how to joinNCT06087653
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Belton, Beverly Hills, Boston, Chicago, Cincinnati, Cleveland, Clovis, Coral Gables, Dallas, Deerfield Beach, Doral, Encino, Evanston, Fargo, Fort Collins, Fresno, Glenview, Goodyear, Greeley, Greenville, Hawthorne, Highland Park, Hollywood, Houston, Independence, Indianapolis, Irvine, Kansas City, Lake Success, Leawood, Lincoln, Longmont, Los Angeles, Loveland, Lubbock, Madison, Manhasset, Merriam, Miami, Mobile, Morgantown, Morristown, Nashville, New Hyde Park, Newport Beach, Panorama City, Pittsburgh, Plantation, Providence, Sacramento, Springfield, Sugar Land, Tamarac, Temple, The Woodlands, Valhalla, Zion
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00